Find Renal Cell Carcinoma (RCC) Clinical Trials Near You
A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Status: Recruiting
Location: See all (9) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.
• For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.
• For part 2: Participants must have had at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other).
• Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Locations
United States
Massachusetts
Dana-Farber Cancer Institute
RECRUITING
Boston
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Pennsylvania
Fox Chase Cancer Center
RECRUITING
Philadelphia
Tennessee
SCRI Oncology Partners
RECRUITING
Nashville
Texas
START San Antonio
RECRUITING
San Antonio
Other Locations
Canada
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITING
Calgary
France
Gustave Roussy
RECRUITING
Villejuif
Spain
Local Institution - 0018
NOT_YET_RECRUITING
Barcelona
Local Institution - 0015
NOT_YET_RECRUITING
Córdoba
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.